Published in Obesity and Diabetes Week, September 27th, 2004
Primary factors driving the rise in drug treatment in this population include increasing awareness of its coronary heart disease risk coupled with the availability of low-cost, generic statin substitutes to treat these patients.
The new Pharmacor study entitled "Dyslipidemia" also finds that Pfizer and Merck plan to fight back against generic erosion of atorvastatin and simvastatin, two leading statins.
"The launch of Pfizer's atorvastatin/torcetrapib and atorvastatin/amlodipine, and of Merck/Schering-Plough's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.